A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen

Molecular Pharmaceutics

Volumn 10, Issue 8, 2013, Pages 2975-2985

  Hao, Guiyang ^a   Kumar, Amit ^a   Dobin, Timothy ^a   Öz, Orhan K ^a   Hsieh, Jer Tsong ^a   Sun, Xiankai ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

64Cu; multivalency; PET; prostate cancer; PSMA

Indexed keywords

2 [11 (CARBOXYMETHYL) 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECAN 4 YL)PENTANEDIOIC ACID; 2,2' (1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE 4,11 DIYL)DIPENTANEDIOIC ACID; 2[(3 AMINO 3 CARBOXYPROPYL)(HYDROXY)(PHOSPHINYL)METHYL]PENTANE 1,5 DIOIC ACID); ANION; CHELATING AGENT; COPPER 64; MEMBRANE ANTIGEN; PHOSPHATE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL STRAIN LNCAP; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; IMAGE ANALYSIS; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYNTHESIS; TUMOR VOLUME;

ANIMALS; ANIONS; CELL LINE, TUMOR; HUMANS; MALE; MICE, SCID; MOLECULAR PROBES; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84881336708     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4000844     Document Type: Article

References (44)

1. Emonds, K. M.; Swinnen, J. V.; Mortelmans, L.; Mottaghy, F. M. Molecular imaging of prostate cancer Methods 2009, 48 (2) 193-9
2. Vees, H.; Buchegger, F.; Albrecht, S.; Khan, H.; Husarik, D.; Zaidi, H.; Soloviev, D.; Hany, T. F.; Miralbell, R. F-18-choline and/or C-11-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (< 1 ng/mL) after radical prostatectomy BJU Int. 2007, 99 (6) 1415-1420
3. Giovacchini, G.; Gajate, A. M.; Messa, C.; Fazio, F. Increased C-11 choline uptake in pagetic bone in a patient with coexisting skeletal metastases from prostate cancer Clin. Nucl. Med. 2008, 33 (11) 797-8
4. Albrecht, S.; Buchegger, F.; Soloviev, D.; Zaidi, H.; Vees, H.; Khan, H. G.; Keller, A.; Bischof Delaloye, A.; Ratib, O.; Miralbell, R. (11)C-acetate PET in the early evaluation of prostate cancer recurrence Eur. J. Nucl. Med. Mol. Imaging 2007, 34 (2) 185-96
5. Ponde, D. E.; Dence, C. S.; Oyama, N.; Kim, J.; Tai, Y. C.; Laforest, R.; Siegel, B. A.; Welch, M. J. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging-in vivo evaluation of 18F-fluoroacetate versus 11C-acetate J. Nucl. Med. 2007, 48 (3) 420-8
6. Rogers, B. E.; Bigott, H. M.; McCarthy, D. W.; Della Manna, D.; Kim, J.; Sharp, T. L.; Welch, M. J. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a Cu-64-labeled bombesin analogue Bioconjugate Chem. 2003, 14 (4) 756-763
7. Zhang, X.; Cai, W.; Cao, F.; Schreibmann, E.; Wu, Y.; Wu, J. C.; Xing, L.; Chen, X. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer J. Nucl. Med. 2006, 47 (3) 492-501
8. Bouchelouche, K.; Capala, J.; Oehr, P. Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer Curr. Opin. Oncol. 2009, 21 (5) 469-74
9. Bander, N. H. Technology insight: monoclonal antibody imaging of prostate cancer Nat. Clin. Pract. Urol. 2006, 3 (4) 216-25
10. Wright, G. L., Jr.; Grob, B. M.; Haley, C.; Grossman, K.; Newhall, K.; Petrylak, D.; Troyer, J.; Konchuba, A.; Schellhammer, P. F.; Moriarty, R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy Urology 1996, 48 (2) 326-34
11. Sweat, S. D.; Pacelli, A.; Murphy, G. P.; Bostwick, D. G. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases Urology 1998, 52 (4) 637-40
12. Jain, R. K. Transport of molecules, particles, and cells in solid tumors Annu. Rev. Biomed. Eng. 1999, 1, 241-63
13. Holland, J. P.; Divilov, V.; Bander, N. H.; Smith-Jones, P. M.; Larson, S. M.; Lewis, J. S. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo J. Nucl. Med. 2010, 51 (8) 1293-300
14. Akhtar, N. H.; Pail, O.; Saran, A.; Tyrell, L.; Tagawa, S. T. Prostate-specific membrane antigen-based therapeutics Adv. Urol. 2012, 2012, 973820
15. Banerjee, S. R.; Foss, C. A.; Castanares, M.; Mease, R. C.; Byun, Y.; Fox, J. J.; Hilton, J.; Lupold, S. E.; Kozikowski, A. P.; Pomper, M. G. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) J. Med. Chem. 2008, 51 (15) 4504-17
16. Kularatne, S. A.; Wang, K.; Santhapuram, H. K.; Low, P. S. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand Mol. Pharmaceutics 2009, 6 (3) 780-9
17. Banerjee, S. R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Green, G.; Fox, J. J.; Horti, A.; Mease, R. C.; Pomper, M. G. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer J. Med. Chem. 2010, 53 (14) 5333-41
18. Hillier, S. M.; Kern, A. M.; Maresca, K. P.; Marquis, J. C.; Eckelman, W. C.; Joyal, J. L.; Babich, J. W. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy J. Nucl. Med. 2011, 52 (7) 1087-93
19. Nedrow-Byers, J. R.; Jabbes, M.; Jewett, C.; Ganguly, T.; He, H.; Liu, T.; Benny, P.; Bryan, J. N.; Berkman, C. E. A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent Prostate 2012, 72 (8) 904-12
20. Humblet, V.; Lapidus, R.; Williams, L. R.; Tsukamoto, T.; Rojas, C.; Majer, P.; Hin, B.; Ohnishi, S.; De Grand, A. M.; Zaheer, A.; Renze, J. T.; Nakayama, A.; Slusher, B. S.; Frangioni, J. V. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen Mol. Imaging 2005, 4 (4) 448-62
21. Robinson, M. B.; Blakely, R. D.; Couto, R.; Coyle, J. T. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain J. Biol. Chem. 1987, 262 (30) 14498-506
22. Misra, P.; Humblet, V.; Pannier, N.; Maison, W.; Frangioni, J. V. Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy J. Nucl. Med. 2007, 48 (8) 1379-89
23. Humblet, V.; Misra, P.; Bhushan, K. R.; Nasr, K.; Ko, Y. S.; Tsukamoto, T.; Pannier, N.; Frangioni, J. V.; Maison, W. Multivalent Scaffolds for Affinity Maturation of Small Molecule Cell Surface Binders and Their Application to Prostate Tumor Targeting J. Med. Chem. 2009, 52 (2) 544-50
24. Zhou, Y.; Chakraborty, S.; Liu, S. Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT Theranostics 2011, 1, 58-82
25. Liu, W.; Hao, G. Y.; Long, M. A.; Anthony, T.; Hsieh, J. T.; Sun, X. K. Imparting Multivalency to a Bifunctional Chelator: A Scaffold Design for Targeted PET Imaging Probes Angew. Chem., Int. Ed. 2009, 48 (40) 7346-9
26. Singh, A. N.; Liu, W.; Hao, G.; Kumar, A.; Gupta, A.; Oz, O. K.; Hsieh, J. T.; Sun, X. Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency Bioconjugate Chem. 2011, 22 (8) 1650-62
27. Banerjee, S. R.; Pullambhatla, M.; Shallal, H.; Lisok, A.; Mease, R. C.; Pomper, M. G. A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA) Oncotarget 2011, 2 (12) 1244-53
28. Hao, G.; Singh, A. N.; Oz, O. K.; Sun, X. Recent advances in copper radiopharmaceuticals Curr. Radiopharm. 2011, 4 (2) 109-21
29. Jackson, P. F.; Tays, K. L.; Maclin, K. M.; Ko, Y. S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X. C.; Wozniak, K.; Slusher, B. S. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors J. Med. Chem. 2001, 44 (24) 4170-5
30. Selvam, C.; Oueslati, N.; Lemasson, I. A.; Brabet, I.; Rigault, D.; Courtiol, T.; Cesarini, S.; Triballeau, N.; Bertrand, H. O.; Goudet, C.; Pin, J. P.; Acher, F. C. A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists J. Med. Chem. 2010, 53 (7) 2797-813
31. Zeng, B. Q.; Wong, K. K.; Pompliano, D. L.; Reddy, S.; Tanner, M. E. A phosphinate inhibitor of the meso-diaminopimelic acid-adding enzyme (MurE) of peptidoglycan biosynthesis J. Org. Chem. 1998, 63 (26) 10081-5
32. Feng, Y.; Coward, J. K. Prodrug forms of N-[(4-deoxy-4-amino-10-methyl) pteroyl]glutamate-gamma-[psiP(O)(OH)]-glutar ate, a potent inhibitor of folylpoly-gamma-glutamate synthetase: synthesis and hydrolytic stability J. Med. Chem. 2006, 49 (2) 770-88
33. Hausner, S. H.; Abbey, C. K.; Bold, R. J.; Gagnon, M. K.; Marik, J.; Marshall, J. F.; Stanecki, C. E.; Sutcliffe, J. L. Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model Cancer Res. 2009, 69 (14) 5843-50
34. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues Clin. Cancer Res. 1997, 3 (1) 81-5
35. Kinoshita, Y.; Kuratsukuri, K.; Landas, S.; Imaida, K.; Rovito, P. M., Jr.; Wang, C. Y.; Haas, G. P. Expression of prostate-specific membrane antigen in normal and malignant human tissues World J. Surg. 2006, 30 (4) 628-36
36. Rajasekaran, S. A.; Anilkumar, G.; Oshima, E.; Bowie, J. U.; Liu, H.; Heston, W.; Bander, N. H.; Rajasekaran, A. K. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen Mol. Biol. Cell 2003, 14 (12) 4835-45
37. Barrett, J.; LaFrance, N.; Coleman, R. E.; Goldsmith, S.; Stubbs, J.; Petry, N.; Vallabhajosula, S.; Maresca, K.; Femia, F.; Babich, J. Targeting metastatic prostate cancer [PCa] in patients with 123I-MIP1072 & 123I-MIP1095 J. Nucl. Med. 2009, 50 (Suppl.) 522
38. Schulke, N.; Varlamova, O. A.; Donovan, G. P.; Ma, D. S.; Gardner, J. P.; Morrissey, D. M.; Arrigale, R. R.; Zhan, C. C.; Chodera, A. J.; Surowitz, K. G.; Maddon, P. J.; Heston, W. D. W.; Olson, W. C. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (22) 12590-5
39. Liu, H.; Rajasekaran, A. K.; Moy, P.; Xia, Y.; Kim, S.; Navarro, V.; Rahmati, R.; Bander, N. H. Constitutive and antibody-induced internalization of prostate-specific membrane antigen Cancer Res. 1998, 58 (18) 4055-60
40. Liu, T.; Wu, L. Y.; Kazak, M.; Berkman, C. E. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen Prostate 2008, 68 (9) 955-64
41. Rajasekaran, A. K.; Anilkumar, G.; Christiansen, J. J. Is prostate-specific membrane antigen a multifunctional protein? Am. J. Physiol. 2005, 288 (5) C975-C981
42. Liu, T.; Toriyabe, Y.; Kazak, M.; Berkman, C. E. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics Biochemistry 2008, 47 (48) 12658-60
43. Liu, T.; Wu, L. Y.; Hopkins, M. R.; Choi, J. K.; Berkman, C. E. A targeted low molecular weight near-infrared fluorescent probe for prostate cancer Bioorg. Med. Chem. Lett. 2010, 20 (23) 7124-6
44. Evans, M. J.; Smith-Jones, P. M.; Wongvipat, J.; Navarro, V.; Kim, S.; Bander, N. H.; Larson, S. M.; Sawyers, C. L. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (23) 9578-82